Indication
Stage IVB Uterine Corpus Cancer AJCC v8
5 clinical trials
8 products
4 drugs
Clinical trial
A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial CarcinomaStatus: Active (not recruiting), Estimated PCD: 2028-08-31
Product
EverolimusProduct
LetrozoleProduct
RibociclibClinical trial
Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersStatus: Recruiting, Estimated PCD: 2024-10-01
Product
TalazoparibClinical trial
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic CancersStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Product
IpilimumabClinical trial
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxStatus: Recruiting, Estimated PCD: 2026-09-01
Drug
AtezolizumabDrug
T-VECProduct
CabozantinibDrug
AbraxaneClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideProduct
Neoantigen Peptide VaccineProduct
Pembrolizumab